Projects per year
Personal profile
Personal profile
Professor Eyad Elkord has currently a Professor position with the Department of Biological Sciences, College of Science, Xi'an Jiaotong-Liverpool University, Suzhou, China; and an Honorary Professor position with University of Salford, UK. Before joining XJTLU, he was a Professor of Immunology with the Department of Applied Biology, College of Science, University of Sharjah, United Arab Emirates.
After obtaining his PhD in Tumor Immunology from University of Wales College of Medicine, Cardiff University (UK), he worked as a Postdoctoral Scientist (Jan 2005 - Dec 2007) at the Paterson Institute for Cancer Research, University of Manchester (UK), and was then promoted to a Research Fellow/Group Leader of the Clinical Immunotherapy Laboratory at the University of Manchester (Jan 2008 - Nov 2010). He then undertook a Lecturer position with the University of Salford (Dec 2010 - July 2012) and was promoted in August 2012 to a Senior Lecturer. He moved to the College of Medicine & Health Science, United Arab Emirates University, in 2012 and was an Associate Professor of Immunology until September 2016. He then worked as a Principal Investigator at Qatar Biomedical Research Institute and a Professor at Hamad Bin Khalifa University, Qatar (July 2016 - Nov 2020) and he also had an Honorary Professor position at the Institute of Cancer Sciences-University of Manchester, UK.
Professor Elkord is a member of several highly regarded scientific societies and an editorial board member for peer-reviewed international journals such as Frontiers in Immunology & Oncology (specialty Cancer Immunity & Immunotherapy), BMC Cancer, Vaccines, Heliyon and Journal of Immunology Research. He is the Editor-in-Chief for the newly established journal "Cancer Immunology Connect". He is a reviewer to many international journals and well-known funding agents, such as the UK Medical Research Council, European Research Council, Dutch Research Council. Dr Elkord has more than 135 publications in peer-reviewed high-impact international journals with more than 12300 citations and an h-index of 48 and M-index of 2.7. In recognition of his research influence, Prof. Elkord has been named in Stanford University’s yearly and career global lists of the top 2% of scientists for four consecutive years (2019-2022), achieving the position in the top 0.26% in the Immunology subfield.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Related documents
Education/Academic qualification
Master, Postgraduate Certificate of Academic Practice, University of Salford
5 Jan 2011 → 5 Jan 2012
Award Date: 31 Jan 2012
PhD, Tumor Immunology, Cardiff University
1 Oct 2001 → 31 Dec 2004
Award Date: 5 Jan 2005
Master, Clinical Biochemistry, University of Bergen
1 Aug 1999 → 30 Jun 2001
Award Date: 31 Aug 2001
Bachelor, Medical Technology, Al-Quds University
1 Apr 1991 → 31 Dec 1994
Award Date: 31 May 1995
External positions
Honorary Professor , University of Salford
1 Dec 2013 → …
Keywords
- QR180 Immunology
- RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Person Types
- Staff
Fingerprint
Collaborations and top research areas from the last five years
Projects
- 2 Not started
-
NSFC General Program: The mechanism of ammonia accumulation promotes liver cancer progression via calcium channel-mTORC2-SREBP1-lipogenesis dependent manner
Dai, W., Hamada, K., Elkord, E. & Cheng, K.
1/01/25 → 31/12/28
Project: Governmental Research Project
File -
The mechanism of ammonia accumulation promotes liver cancer progression via calcium channel-mTORC2-SREBP1-lipogenesis dependent manner
Dai, W., Wang, S., Chen, G., Elkord, E., Hamada, K., Cheng, K., Xu, J., Huang, S., Yang, C., Ma, J. & Bin, U.
1/01/25 → 31/12/28
Project: Governmental Research Project
-
Editorial: Novel biomarkers in tumor immunity and immunotherapy
Matsutani, T., Akbay, E. & Elkord, E., 8 Apr 2024, In: Frontiers in Immunology. 15, 1405082.Research output: Contribution to journal › Editorial
Open Access -
Effects of 1H-1,2,3-Triazole Derivatives of 3-O-Acetyl-11-Keto-Beta-Boswellic Acid from Boswellia sacra Resin on T-Cell Proliferation and Activation
Elkord, E., 8 Dec 2024, In: Pharmaceuticals.Research output: Contribution to journal › Article › peer-review
-
Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials
Elkord, E., 26 Nov 2024, In: Frontiers in Immunology. 15, 1501613Research output: Contribution to journal › Review article › peer-review
-
Temporal patterns of cancer burden in Asia, 1990–2019: a systematic examination for the Global Burden of Disease 2019 study
GBD 2019 Asia and All Cancers Collaborators & Elkord, E., Feb 2024, In: The Lancet Regional Health - Southeast Asia. 21, 100333.Research output: Contribution to journal › Article › peer-review
Open Access -
Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?
Elkord, E., 22 Nov 2024, In: Vaccines.Research output: Contribution to journal › Review article › peer-review
Activities
-
Discovery and validation of novel targets in T regulatory cells in type 1 diabetes patients
Eyad Elkord (Supervisor)
1 Jan 2025 → 31 Dec 2028Activity: Supervision › PhD Supervision
-
International Association of Biomedical Sciences (iABS)
Eyad Elkord (Keynote speaker)
5 Dec 2024Activity: Talk or presentation › Invited talk
-
Frontiers in Immunology (Journal)
Eyad Elkord (Reviewer)
26 Nov 2024Activity: Peer-review and editorial work of publications › Publication Peer-review
-
Discovery and validation of novel small-molecule inhibitors against Lymphocyte Activation Gene-3 (LAG-3) for cancer immunotherapy.
Eyad Elkord (Supervisor)
1 Sept 2024 → 31 Aug 2028Activity: Supervision › PhD Supervision
-
Discovery and validation of peptide-based structural analogues of ligands targeting TIGIT.
Eyad Elkord (Supervisor)
1 Sept 2024 → 31 Aug 2028Activity: Supervision › PhD Supervision